- Home
- CNTA vs NAMS Comparison
CNTA vs NAMS Comparison
Compare CNTA & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNTA | NAMS |
|---|---|---|
| Founded | 2020 | 2019 |
| Country | United Kingdom | Netherlands |
| Employees | N/A | 100 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.5B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | CNTA | NAMS |
|---|---|---|
| Price | $39.85 | $32.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | $42.50 | ★ $46.75 |
| AVG Volume (30 Days) | ★ 3.2M | 804.1K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.13 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $15,000,000.00 | N/A |
| Revenue This Year | N/A | $25.64 |
| Revenue Next Year | N/A | $530.85 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.60 | $14.06 |
| 52 Week High | $40.26 | $42.00 |
Technical Indicators
Market Signals| Indicator | CNTA | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 78.06 | 55.68 |
| Support Level | $22.49 | $29.73 |
| Resistance Level | N/A | $37.43 |
| Average True Range (ATR) | 1.66 | 1.76 |
| MACD | 1.11 | 0.37 |
| Stochastic Oscillator | 97.05 | 86.11 |
Price Performance
Historical ComparisonAbout CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.